Thermo Fisher Scientific Inc.

The forensic scores point in different directions, so they are best read together rather than as a single verdict. The Beneish M-Score for 2024 is -2.579. Its label places it below -1.78, outside the elevated manipulation-risk zone. In plain terms, this screening model did not flag the 2024 figures for a closer read, though a screen is not a clearance. The Altman Z-Score variant shown here is 3.97, in the safe zone, meaning the model does not indicate near-term financial distress. The operating cash flow to net income ratio of 1.37 for 2024 means operating cash flow of $8.67 billion exceeded net income of $6.34 billion, a supportive sign for cash-based earnings quality. The 2025 nine-month picture is less favorable: operating cash flow of $4.36 billion compares with net income of $4.75 billion, a ratio of roughly 0.92. That ratio is a simple calculation from the 10-Q, not a forensic score. Working capital absorbed cash as inventories rose to $5.75 billion from $4.98 billion and accounts receivable rose to $8.91 billion from $8.19 billion. Readers may want to look at whether these increases reverse in later quarters. Revenue in 2024 was essentially flat at $42.88 billion versus $42.86 billion, so the rise in operating income to $7.34 billion from $6.86 billion came against a static top line. The excerpt defers to the 2024 10-K for risk factors and points to Note 5 for product liability and intellectual property claims, so the legal exposure can only be weighed by consulting those documents. Overall, the figures show a business still generating substantial cash and passing the screens provided, while the 2025 trends in cash conversion, debt, and buybacks deserve closer attention.

Catalyst.Management's discussion in the 10-Q excerpt is mostly a cross-reference to the 2024 Form 10-K and states that critical accounting policies did not change in the first nine months of 2025. The reported results show growth: nine-month revenues were $32.34 billion, up from $31.48 billion, and operating income rose to $5.49 billion from $5.32 billion. Third-quarter revenues were $11.12 billion versus $10.60 billion. Growth has been accompanied by acquisitions, which used $4.04 billion of cash in the nine months compared with $3.13 billion a year earlier. The excerpt does not include segment or product commentary, so the drivers beyond these figures are not described here.

Hidden risk.Cash generation weakened while obligations grew. Net cash from operations fell to $4.36 billion for the nine months from $5.38 billion, as changes in assets and liabilities consumed $2.26 billion. Short-term and long-term obligations combined rose to $35.68 billion at September 27, 2025 from $31.28 billion at December 31, 2024, while cash fell to $1.98 billion from $4.01 billion. The 2024 share repurchase authorization of $4.00 billion was fully used by the end of the third quarter, leaving nothing remaining. Risk factors are incorporated by reference from the 2024 10-K and are not reproduced in this excerpt, so readers may want to look at that document's debt and legal sections directly.